Frontiers in immunology
Cure8 research brief
Why This Matters
The case suggests that blocking IL-4/IL-13 (with dupilumab) might rarely trigger Th17-predominant colonic inflammation presenting as ulcerative colitis; patients and clinicians should be alert for new GI symptoms after starting this therapy.
Who Should Pay Attention
Adult patients receiving dupilumab or other IL-4/IL-13 pathway inhibitors, gastroenterologists, dermatologists, and researchers studying immune-pathway interactions or IBD pathogenesis.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper describes a 63-year-old man who developed hematochezia and tenesmus within three months of starting dupilumab. Colonoscopy and histology confirmed ulcerative colitis; stopping dupilumab was followed by clinical and endoscopic remission.
Immunohistochemistry showed increased IL-17 and decreased IL-4 in inflamed mucosa that normalized with recovery, which the authors propose as hypothesis-generating evidence for a Th2-to-Th17 shift. This is a single case report: it cannot establish causation or estimate risk.
Clinicians and patients should view the finding as an alert that new gastrointestinal symptoms after starting IL-4/IL-13 blockade warrant prompt evaluation, including endoscopy and specialist input.
If you are on or considering dupilumab and develop new GI symptoms (bleeding, persistent diarrhea, abdominal pain, urgency), contact your provider so they can consider appropriate testing and multidisciplinary management.
Keep In Mind
This report is a single case (hypothesis-generating) reported in Frontiers in Immunology and the supplied content is an abstract-level summary. It cannot quantify how often this occurs; larger studies or pharmacovigilance data would be needed to assess risk. The immunohistochemical findings support a mechanistic hypothesis but do not prove causality.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in immunology
AuthorsFu F, Zhao Q, Ma L +3 more
Study typeJournal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Severe Pancolitis Presenting with Sacroiliitis: A Case Highlighting the Gut-Joint Axis in Ulcerative Colitis
This case shows that ulcerative colitis can first appear with inflammatory back pain (sacroiliitis) rather than bowel symptoms; recognizing this link can lead to earlier diagnosis and treatment that may help both gut and...
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...